IDH1 and central nervous system cancer: Inactivating mutations in ATRX have been shown to disrupt immune signaling pathways, such as promoting immunosuppressive mechanisms in IDH1-mutant gliomas and impairing cGAS-STING signaling in sarcomas [36–38].